Fatal Kaposi's sarcoma-associated immune reconstitution following HAART initiation

International Journal of STD and AIDS

Volumn 16, Issue 1, 2005, Pages 80-82

  Crane, Heidi M ^a   Deubner, Heike ^b   Huang, Jane C ^b   Swanson, Paul E ^b   Harrington, Robert D ^a  

^a Center for AIDS and STD   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

HAART; HIV; Immune reconstitution; Kaposi's sarcoma

Indexed keywords

CLARITHROMYCIN; CORTICOSTEROID; COTRIMOXAZOLE; EFAVIRENZ; ETHAMBUTOL; GANCICLOVIR; LAMIVUDINE; LEVOFLOXACIN; ZIDOVUDINE;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; COUGHING; DISEASE ASSOCIATION; DISEASE COURSE; FATALITY; FATIGUE; FEVER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNOPATHOLOGY; KAPOSI SARCOMA; MALE; PRIORITY JOURNAL; SKIN DISEASE;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FATAL OUTCOME; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; SARCOMA, KAPOSI;

EID: 13244267367     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/0956462052932647     Document Type: Article

References (14)

1. Stover DE, White DA, Romano PA, Gellene RA, Robeson WA. Spectrum of pulmonary diseases associated with the acquired immune deficiency syndrome. Am J Med 1985;78:429-37
2. Fouret PJ, Touboul JL, Mayaud CM, Akoun GM, Roland J. Pulmonary Kaposi's sarcoma in patients with acquired immune deficiency syndrome: a clinicopathological study. Thorax 1987;42:262-8
3. Garay SM, Belenko M, Fazzini E, Schinella R. Pulmonary manifestations of Kaposi's sarcoma. Chest 1987;91:39-43
4. Miller RF, Tomlinson MC, Cottrill CP, Donald JJ, Spittle MF, Semple SJ. Bronchopulmonary Kaposi's sarcoma in patients with AIDS. Thorax 1992;47:721-5
5. Huang L, Schnapp LM, Gruden JF, Hopewell PC, Stansell JD. Presentation of AIDS-related pulmonary Kaposi's sarcoma diagnosed by bronchoscopy. Am J Respir Crit Care Med 1996;153:1385-90
6. Jacobson MA, Zegans M, Pavan PR, et al. Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy. Lancet 1997;349:1443-5
7. Karavellas MP, Plummer DJ, Macdonald JC, et al. Incidence of immune recovery vitritis in Cytomegalovirus retinitis patients following institution of successful highly active antiretroviral therapy. J Infect Dis 1999;179:697-700
8. Shelburne III SA, Hamill RJ, Rodriguez-Barradas MC, et al. Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy. Medicine (Baltimore) 2002;81:213-27
9. Weir A, Wansbrough-Jones M. Mucosal Kaposi's sarcoma following protease inhibitor therapy in an HIV-infected patient. AIDS 1997;11:1895-6
10. Aboulafia DM. The epidemiologic, pathologic, and clinical features of AIDS-associated pulmonary Kaposi's sarcoma. Chest 2000;117:1128-45
11. Holkova B, Takeshita K, Cheng DM, et al. Effect of highly active antiretroviral therapy on survival in patients with AIDS-associated pulmonary Kaposi's sarcoma treated with chemotherapy. J Clin Oncol 2001;19:3848-51
12. Pellet C, Chevret S, Blum L, et al. Virologic and immunologic parameters that predict clinical response of AIDS-associated Kaposi's sarcoma to highly active antiretroviral therapy. J Invest Dermatol 2001;117:858-63
13. Leitch H, Trudeau M, Routy JP. Effect of protease inhibitor-based highly active antiretroviral therapy on survival in HIV-associated advanced Kaposi's sarcoma patients treated with chemotherapy. HIV Clin Trials 2003;4:107-114
14. Safdar A, Rubocki RJ, Horvath JA, Narayan KK, Waldron RL. Fatal immune restoration disease in human immunodeficiency virus type 1-infected patients with progressive multifocal leukoencephalopathy: impact of antiretroviral therapy-associated immune reconstitution. Clin Infect Dis 2002;35:1250-7